The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 single-arm, open-label study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in patients (pts) with acute myeloid leukemia (AML) in complete response (CR) with measurable residual disease (MRD).
 
Adolfo de la Fuente Burguera
Honoraria - Abbvie; Astellas Pharma; Celgene/Bristol-Myers Squibb; Daiichi Sankyo; Incyte; Janssen-Cilag; Jazz Pharmaceuticals; Novartis; Pfizer; Roche; SERVIER
Consulting or Advisory Role - Abbvie; Astellas Pharma; Celgene/Bristol-Myers Squibb; Curis; Daiichi Sankyo; ImmunoGen; Incyte; Jazz Pharmaceuticals; Novartis; Pfizer; Roche
Speakers' Bureau - Abbvie; Astellas Pharma; Celgene/Bristol-Myers Squibb; Daiichi Sankyo; Incyte; Janssen-Cilag; Jazz Pharmaceuticals; Novartis; Pfizer; Roche; SERVIER
Research Funding - BTG; Janssen-Cilag; Novartis
 
Claudio Cerchione
Honoraria - Abbvie; Amgen; BeiGene; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Menarini; Pfizer; Sanofi/Aventis; SERVIER; Stemline Therapeutics; Takeda
Consulting or Advisory Role - Abbvie; Amgen; BeiGene; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Menarini; Pfizer; Sanofi; SERVIER; Stemline Therapeutics; Takeda
Speakers' Bureau - Abbvie; Amgen; BeiGene; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Menarini; Pfizer; Sanofi/Aventis; SERVIER; Stemline Therapeutics; Takeda
 
Sebastian Scholl
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Novartis; Pfizer; SERVIER; SERVIER
Travel, Accommodations, Expenses - Abbvie; Abbvie; Daiichi Sankyo; Pfizer
 
Jan Moritz Middeke
Research Funding - Novartis
 
Nitika Nitika
Employment - Curis; Fosun Pharma
Stock and Other Ownership Interests - Curis
 
Maureen E Lane
Employment - Curis
Leadership - Curis
Stock and Other Ownership Interests - Curis
Patents, Royalties, Other Intellectual Property - Curis
 
Wanying Zhao
Employment - Curis; Merck (I)
Stock and Other Ownership Interests - Curis; Incyte
 
Steven Angelides
Employment - Curis
Stock and Other Ownership Interests - Curis
Research Funding - Curis
 
Reinhard von Roemeling
Employment - Curis
Leadership - Curis
Stock and Other Ownership Interests - Curis
 
Uwe Platzbecker
Honoraria - Abbvie; Celgene/Jazz; Curis; Geron; Janssen
Consulting or Advisory Role - BMS GmbH & Co. KG; Celgene/Jazz; Novartis
Research Funding - Amgen (Inst); BerGenBio (Inst); Celgene (Inst); Curis (Inst); Janssen (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - part of a patent for a TFR-2 antibody (Rauner et al. Nature Metabolics 2019)
Travel, Accommodations, Expenses - Celgene